ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases

$ 29.99

4.6 (368) In stock

Clinical Validation of the Brain Model Published Online in the Journal NeuroImage ClearPoint Maestro Brain Model ClearPoint Maestro Brain Model ClearPoint Neuro Maestro Brain Model Comparative Reproducibility Error Results Reproducibility error of Maestro (green), FreeSurfer 7.2 (blue) and manual segmentation (red) for common brain structures (left), and average over all structures (right). Bars represent range of measured relative volume difference. SOLANA BEACH, Calif., Feb. 21, 2024 (GLOBE NE
Clinical Validation of the Brain Model Published Online in the Journal NeuroImage ClearPoint Maestro Brain Model ClearPoint Maestro Brain Model ClearPoint

CLPT - ClearPoint Neuro - by Jonah Lupton

Stock Market News 2024-02-21

ClearPoint Neuro wins FDA nod for ClearPoint 2.2 with Maestro Brain Modeling

ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software

CLPT, Detailed Quotes

CLPT - ClearPoint Neuro Announces Pricing of Public Offering of

SNN

ClearPointNeuro (@ClearPointNeuro) / X

ClearPoint Neuro (NasdaqCM:CLPT) Stock Forecast & Analyst Predictions - Simply Wall St

SNN

ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software

ClearPoint Neuro, Inc. on LinkedIn: #clearpoint #nsgy #clpt

CLPT, ClearPoint Neuro Inc

SNN

ClearPoint Neuro, Inc. Announces FDA Clearance and First-In-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model -February 21, 2024 at 04:05 pm EST